Long-term outcome in 42 pediatric liver transplant patients with alpha 1-antitrypsin deficiency: a single-center experience.

Abstract

INTRODUCTION:

We examined the long-term outcome of transplantation for alpha 1-antitrypsin deficiency (A1ATD).

METHOD:

Data were reviewed on 42 transplants in 35 children with A1ATD over 42 yr and compared with 129 transplants in 116 children with biliary atresia (BA).

RESULTS:

Over 50% of patients were followed up for >10 yr. A1ATD were older than BA at transplantation, median age, 6.0 vs. 1.0 yr (p < 0.0001), and transplanted earlier in the course of liver failure (total bilirubin, 2.7 mg/dL [1.4-6.9] vs. 9.7 mg/dL [2.9-15.4], p = 0.005). Patient survival was greater in A1ATD than BA: one-yr post-transplant, 82.7% vs. 67.9%; five yr, 76.5% vs. 60.2%; and 10 yr, 76.5% vs. 55.9% (p = 0.03). Death-censored graft survival was similar: one-yr post-transplant, 68.4% vs. 66.2%; five yr, 68.4% vs. 55.8%; and 10 yr, 68.4% vs. 52.5% (p = 0.2). Deaths were from infection, hemorrhage, and graft failure <6 months post-transplant. Patient survival improved at five yr from 33.3% pre-cyclosporine (CSA) (1969-1984) (n = 6) to 76.5% in the CSA era (1985-1994) (n = 17) and 100% with tacrolimus (1995-2006) (n = 12) (p = 0.007).

CONCLUSIONS:

The age at transplantation and the degree of liver dysfunction were related to the differences in graft and patient survival between A1AT and BA.

• Authors: Michael G Hughes Jr, Khalid M Khan, Angelika C Gruessner, Harvey Sharp, Mark Hill, Tun Jie, Raja Kandaswamy, Abhinav Humar, William D Payne, Rainer W G Gruessner
• Journal: Clinical transplantation (Clin Transplant) 2011 Sep-Oct Vol. 25 Issue 5 Pg. 731-6 ISSN: 1399-0012 [Electronic] Denmark
• PMID: 21077958 (Publication Type: Clinical Trial, Comparative Study, Journal Article)
• Copyright: © 2010 John Wiley & Sons A/S.

Chemical References

• Immunosuppressive Agents

Topics

• Biliary Atresia (mortality)
• Child
• Child, Preschool
• Female
• Follow-Up Studies
• Graft Rejection (drug therapy, mortality)
• Graft Survival (physiology)
• Humans
• Immunosuppressive Agents (therapeutic use)
• Infant
• Infant, Newborn
• Kidney Transplantation (mortality)
• Liver Transplantation (mortality)
• Male
• Prognosis
• Prospective Studies
• Retrospective Studies
• Survival Rate
• alpha 1-Antitrypsin Deficiency (mortality)